FEMRING Side Effects

6994647-6 | Abdominal Distension, Constipation, Crying, Device Difficult To Use, Dysuria, Headache, No Therapeutic Response, Suicidal Ideation, Vaginal Swelling
on Sep 15, 2010 Female patient from UNITED STATES , 48 years of age, weighting 130.0 lb, was treated with Femring (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal distension, constipation (What is constipation?), crying, device difficult to use, dysuria, headache (What is headache?), no therapeutic response, suicidal ideation, vaginal swelling. Femring dosage: I Insert Ring 3 Months. Patient was hospitalized.

6720581-2 | Device Expulsion, Muscle Spasms, Product Adhesion Issue, Vaginal Stricture, Vulvovaginal Adhesion
Patient was taking Femring (View Usage). Patient had the following side effects: device expulsion, muscle spasms, product adhesion issue, vaginal stricture, vulvovaginal adhesion on Apr 29, 2010 from UNITED STATES Additional patient health information: Female patient , 60 years of age, weighting 130.1 lb, . Femring dosage: 0.1 Mg, Qd, Vaginal. During the same period patient was treated with ESTRACE (Daily, Vaginal) (View Estrace Review and Estrace Label ), ACTIVELLA (View Activella Review and Activella Label ), VITAMINS (View Vitamins Review and Vitamins Label ), CALCIUM (CALCIUM GLUBIONATE) (View Calcium (calcium Glubionate) Review and Calcium (calcium Glubionate) Label ), MUCINEX (View Mucinex Review and Mucinex Label ).

6697719-9 | Muscle Spasms, Product Adhesion Issue
Adverse event was reported on Apr 15, 2010 by a Female patient taking Femring (View Usage) (Dosage: 0.1 Mg, Qd, Vaginal) . Location: UNITED STATES , 60 years of age, weighting 130.1 lb, After Femring was administered, patient had the following side effects: muscle spasms, product adhesion issue. During the same period patient was treated with ESTRACE (Daily, Vaginal) (View Estrace Review and Estrace Label ), ACTIVELLA (View Activella Review and Activella Label ), VITAMINS (View Vitamins Review and Vitamins Label ), CALCIUM (CALCIUM GLUBIONATE) (View Calcium (calcium Glubionate) Review and Calcium (calcium Glubionate) Label ), MUCINEX (View Mucinex Review and Mucinex Label ).

6632382-4 | Contusion, Emotional Disorder, Fall, Headache, Hot Flush, Insomnia, Mental Impairment, Migraine With Aura
on Mar 03, 2010 Female patient from UNITED STATES , 65 years of age, weighting 110.0 lb, was treated with Femring (View Usage). Patient experienced the following unwanted or unexpected effects: contusion, emotional disorder, fall (What is fall?), headache (What is headache?), hot flush, insomnia, mental impairment, migraine with aura. Femring dosage: 0.05 Mg Qs, Vaginal.


6621913-6 | Product Adhesion Issue, Vaginal Stricture, Vulvovaginal Adhesion
on Feb 16, 2010 Female patient from UNITED STATES , 60 years of age, weighting 130.1 lb, was treated with Femring (View Usage). Patient had the following side effects: product adhesion issue, vaginal stricture, vulvovaginal adhesion. Femring dosage: 0.1mg, Qd, Vaginal. During the same period patient was treated with ESTRACE (2-3 Times Per Week, Vaginal) (View Estrace Review and Estrace Label ), VITAMINS (View Vitamins Review and Vitamins Label ), CALCIUM (CALCIUM GLUBIONATE) (View Calcium (calcium Glubionate) Review and Calcium (calcium Glubionate) Label ), MUCINEX (View Mucinex Review and Mucinex Label ).

6595878-X | Emotional Disorder, Fall, Headache, Hot Flush, Insomnia, Mental Impairment, Migraine With Aura, Nausea
Patient was taking Femring (View Usage). After Femring was administered, patient had the following side effects: emotional disorder, fall (What is fall?), headache (What is headache?), hot flush, insomnia, mental impairment, migraine with aura, nausea (What is nausea?) on Feb 02, 2010 from UNITED STATES Additional patient health information: Female patient , 65 years of age, weighting 110.0 lb, . Femring dosage: 0.05 Mg, Qd, Vaginal.

6539723-7 | Emotional Disorder, Fall, Headache, Hot Flush, Insomnia, Joint Injury, Mental Impairment, Migraine With Aura
Adverse event was reported on Dec 29, 2009 by a Female patient taking Femring (View Usage) (Dosage: 0.05 Mg, Qd, Vagincal) . Location: UNITED STATES , 65 years of age, weighting 110.0 lb, Patient experienced the following unwanted or unexpected effects: emotional disorder, fall (What is fall?), headache (What is headache?), hot flush, insomnia, joint injury, mental impairment, migraine with aura.

6486205-7 | Complication Of Device Removal, Gastric Haemorrhage, Rectal Haemorrhage, Vulvovaginal Burning Sensation, Vulvovaginal Dryness, Vulvovaginal Mycotic Infection, Vulvovaginal Pain
on Nov 24, 2009 Female patient from UNITED STATES , 66 years of age, weighting 155.0 lb, was diagnosed with bladder disorder, menopausal symptoms, arthritis (What is arthritis?) and was treated with Femring (View Usage). Patient had the following side effects: complication of device removal, gastric haemorrhage, rectal haemorrhage, vulvovaginal burning sensation, vulvovaginal dryness, vulvovaginal mycotic infection, vulvovaginal pain. Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with LISINOPRIL (View Lisinopril Review and Lisinopril Label ). Patient was hospitalized.

6387451-3 | Breast Tenderness, Oophorectomy, Ovarian Mass, Vulvovaginal Pruritus
on Sep 15, 2009 Female patient from UNITED STATES , 52 years of age, weighting 125.0 lb, was diagnosed with hot flush, night sweats and was treated with Femring (View Usage). After Femring was administered, patient had the following side effects: breast tenderness, oophorectomy, ovarian mass, vulvovaginal pruritus. Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with VALIUM /000170011 (DIAZEPAM) (View Valium /000170011 (diazepam) Review and Valium /000170011 (diazepam) Label ), XANAX (View Xanax Review and Xanax Label ), LOMOTIL /00034001/ (ATROPINE SULFATE, DIPHENOXYLATE HYDROCHLORIDE) (View Lomotil /00034001/ (atropine Sulfate, Diphenoxylate Hydrochloride) Review and Lomotil /00034001/ (atropine Sulfate, Diphenoxylate Hydrochloride) Label ), CELEBREX (View Celebrex Review and Celebrex Label ), ACIPHEX (View Aciphex Review and Aciphex Label ).

6303758-X | Condition Aggravated, Ovarian Cyst
Patient was taking Femring (View Usage). Patient experienced the following unwanted or unexpected effects: condition aggravated, ovarian cyst (What is ovarian cyst?) on Jul 27, 2009 from UNITED STATES Additional patient health information: Female patient , 84 years of age, was diagnosed with prophylaxis urinary tract infection and. Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with MULTIVITAMIN /00831701/ (VITAMINS NOS) (View Multivitamin /00831701/ (vitamins Nos) Review and Multivitamin /00831701/ (vitamins Nos) Label ), VERAPAMIL (View Verapamil Review and Verapamil Label ).

6186734-X | Abdominal Pain, Headache, Loss Of Consciousness, Motor Dysfunction, Pain In Extremity
Adverse event was reported on May 08, 2009 by a Female patient taking Femring (View Usage) (Dosage: Vaginal Ring Per 3 Months Vag) . Location: UNITED STATES , 33 years of age, weighting 185.0 lb, Patient had the following side effects: abdominal pain (What is abdominal pain?), headache (What is headache?), loss of consciousness, motor dysfunction, pain in extremity. Patient was hospitalized.

6094751-3 | Intervertebral Disc Protrusion, Product Quality Issue
on Feb 16, 2009 Female patient from UNITED STATES , 58 years of age, weighting 108.9 lb, was diagnosed with menopausal symptoms, hot flush and was treated with Femring (View Usage). After Femring was administered, patient had the following side effects: intervertebral disc protrusion, product quality issue. Femring dosage: .05 Mg, Qd, Vaginal. During the same period patient was treated with NEXIUM (View Nexium Review and Nexium Label ).

5914433-5 | Headache, Nail Disorder, Onychomadesis, Staphylococcal Infection
on Sep 23, 2008 Female patient from UNITED STATES , 53 years of age, weighting 119.9 lb, was diagnosed with menopausal symptoms and was treated with Femring (View Usage). Patient experienced the following unwanted or unexpected effects: headache (What is headache?), nail disorder, onychomadesis, staphylococcal infection (What is staphylococcal infection?). Femring dosage: 0.1 Mg, Qd, Vaginal. During the same period patient was treated with NAPROSYN /00256201/ (NAPROXEN) (View Naprosyn /00256201/ (naproxen) Review and Naprosyn /00256201/ (naproxen) Label ), ACYCLOVIR /00587301/ (ACICLOVIR) (View Acyclovir /00587301/ (aciclovir) Review and Acyclovir /00587301/ (aciclovir) Label ).

5663427-6 | Abdominal Discomfort, Abdominal Distension, Abdominal Tenderness, Alanine Aminotransferase Increased, Aphasia, Balance Disorder, Blood Glucose Increased, Breast Tenderness, Confusional State
Patient was taking Femring (View Usage). Patient had the following side effects: abdominal discomfort, abdominal distension, abdominal tenderness, alanine aminotransferase increased, aphasia (What is aphasia?), balance disorder, blood glucose increased, breast tenderness, confusional state on Feb 22, 2008 from UNITED STATES Additional patient health information: Female patient , 45 years of age, weighting 158.1 lb, . Femring dosage: .05 Mg, Qd, Vaginal. During the same period patient was treated with CENESTIN (View Cenestin Review and Cenestin Label ), FLEXERIL /00428402/(CYCLOBENZAPRINE HYDROCHLORIDE) TABLET (View Flexeril /00428402/(cyclobenzaprine Hydrochloride) Tablet Review and Flexeril /00428402/(cyclobenzaprine Hydrochloride) Tablet Label ), IMITREX /01044801/(SUMATRIPTAN) TABLET (View Imitrex /01044801/(sumatriptan) Tablet Review and Imitrex /01044801/(sumatriptan) Tablet Label ).

5623826-5 | Abdominal Discomfort, Abdominal Distension, Abdominal Pain, Abdominal Tenderness, Alanine Aminotransferase Increased, Anorexia, Aphasia, Balance Disorder, Blood Glucose Increased
Adverse event was reported on Jan 24, 2008 by a Female patient taking Femring (View Usage) (Dosage: 0.05 Mg,qd; Vaginal) . Location: UNITED STATES , 45 years of age, weighting 158.1 lb, After Femring was administered, patient had the following side effects: abdominal discomfort, abdominal distension, abdominal pain (What is abdominal pain?), abdominal tenderness, alanine aminotransferase increased, anorexia, aphasia (What is aphasia?), balance disorder, blood glucose increased. During the same period patient was treated with CENESTIN (View Cenestin Review and Cenestin Label ), FLEXERIL /00428401/ (CYCLOBENZAPRINE HYDROCHLORIDE) TABLET, 10 MG (View Flexeril /00428401/ (cyclobenzaprine Hydrochloride) Tablet, 10 Mg Review and Flexeril /00428401/ (cyclobenzaprine Hydrochloride) Tablet, 10 Mg Label ), IMITREX /01044801/ (SUMATRIPTAN) TABLET), 100 MG (View Imitrex /01044801/ (sumatriptan) Tablet), 100 Mg Review and Imitrex /01044801/ (sumatriptan) Tablet), 100 Mg Label ).

5604271-5 | Endometrial Disorder, Ovarian Cyst, Vaginal Candidiasis
on Jan 14, 2008 Female patient from UNITED STATES , 53 years of age, was diagnosed with menopausal symptoms and was treated with Femring (View Usage). Patient experienced the following unwanted or unexpected effects: endometrial disorder, ovarian cyst (What is ovarian cyst?), vaginal candidiasis. Femring dosage: 0.05mg, Qd, Oral. Patient was hospitalized.

5504042-4 | Chest Pain, Heart Rate Irregular, Hormone Level Abnormal, Hot Flush, Loss Of Consciousness, Medical Device Complication, Night Sweats
on Oct 18, 2007 Female patient from UNITED STATES , 34 years of age, weighting 115.1 lb, was diagnosed with vulvovaginal discomfort, vulvovaginal dryness and was treated with Femring (View Usage). Patient had the following side effects: chest pain (What is chest pain?), heart rate irregular, hormone level abnormal, hot flush, loss of consciousness, medical device complication, night sweats. Femring dosage: 0.1 Mg, Qd, Vaginal. During the same period patient was treated with NADOLOL (20 Mg, Bid, Oral) (View Nadolol Review and Nadolol Label ), LIPITOR (View Lipitor Review and Lipitor Label ), CARDIZEM (View Cardizem Review and Cardizem Label ), PREMARIN (View Premarin Review and Premarin Label ), DEPO ESTRADIOL (CHLOROBUTANOL, ESTRADIOL CIPIONATE, GOSSYPIUM SPP. SEE (View Depo-estradiol (chlorobutanol, Estradiol Cipionate, Gossypium Spp. See Review and Depo-estradiol (chlorobutanol, Estradiol Cipionate, Gossypium Spp. See Label ). Patient was hospitalized.

5489147-9 | Anxiety, Autonomic Nervous System Imbalance, Chest Pain, Decreased Appetite, Depression, Disease Recurrence, Dizziness, Hormone Level Abnormal
Patient was taking Femring (View Usage). After Femring was administered, patient had the following side effects: anxiety (What is anxiety?), autonomic nervous system imbalance, chest pain (What is chest pain?), decreased appetite, depression (What is depression?), disease recurrence, dizziness (What is dizziness?), hormone level abnormal on Oct 01, 2007 from UNITED STATES Additional patient health information: Female patient , 34 years of age, weighting 115.1 lb, was diagnosed with vulvovaginal discomfort, vulvovaginal dryness and. Femring dosage: 0.1 Mg, Qd, Vaginal; 0.1 Mg, Qd, Vaginal. During the same period patient was treated with LIPITOR (View Lipitor Review and Lipitor Label ), CARDIZEM (View Cardizem Review and Cardizem Label ), PREMARIN (View Premarin Review and Premarin Label ), DEPO ESTRADIOL /01394001/ (CHLOROBUTANOL, ESTRADIOL CIPIONATE, GOSSYPI (View Depo-estradiol /01394001/ (chlorobutanol, Estradiol Cipionate, Gossypi Review and Depo-estradiol /01394001/ (chlorobutanol, Estradiol Cipionate, Gossypi Label ), REMERON (View Remeron Review and Remeron Label ). Patient was hospitalized.

5449522-5 | Disease Recurrence, Rheumatoid Arthritis, Vulvovaginal Mycotic Infection
Adverse event was reported on Aug 27, 2007 by a Female patient taking Femring (View Usage) (Dosage: 0.1 Mg, Qd, Vaginal) was diagnosed with artificial menopause and. Location: UNITED STATES , 40 years of age, weighting 119.9 lb, Patient experienced the following unwanted or unexpected effects: disease recurrence, rheumatoid arthritis (What is rheumatoid arthritis?), vulvovaginal mycotic infection. During the same period patient was treated with SYNTHROID (View Synthroid Review and Synthroid Label ).

5392986-6 | Biopsy Cervix Abnormal, Chest Pain, Dizziness, Fatigue, Feeling Abnormal, Heart Rate Irregular, Ovarian Cyst, Throat Irritation, Uterine Enlargement
on Jul 11, 2007 Female patient from UNITED STATES , 72 years of age, weighting 153.9 lb, was diagnosed with vulvovaginal dryness and was treated with Femring (View Usage). Patient had the following side effects: biopsy cervix abnormal, chest pain (What is chest pain?), dizziness (What is dizziness?), fatigue, feeling abnormal, heart rate irregular, ovarian cyst (What is ovarian cyst?), throat irritation, uterine enlargement. Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with AMIODARONE HCL (View Amiodarone Hcl Review and Amiodarone Hcl Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), HYZAAR (View Hyzaar Review and Hyzaar Label ), IMDUR (View Imdur Review and Imdur Label ), LOPRESSOR (View Lopressor Review and Lopressor Label ), LUNESTA (View Lunesta Review and Lunesta Label ), NITROSTAT (View Nitrostat Review and Nitrostat Label ), ZANTAC 150 (View Zantac 150 Review and Zantac 150 Label ). Patient was hospitalized.

5379555-9 | Histoplasmosis, Medical Device Complication, Pneumonia, Procedural Pain, Skeletal Injury
on Jun 20, 2007 Female patient from UNITED STATES , 56 years of age, weighting 194.9 lb, was treated with Femring (View Usage). After Femring was administered, patient had the following side effects: histoplasmosis, medical device complication, pneumonia (What is pneumonia?), procedural pain, skeletal injury. Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with SYNTHROID (View Synthroid Review and Synthroid Label ), ACIPHEX (View Aciphex Review and Aciphex Label ), VALIUM (View Valium Review and Valium Label ), CLONIDINE (View Clonidine Review and Clonidine Label ), BUPROPION HCL (View Bupropion Hcl Review and Bupropion Hcl Label ), LIPITOR (View Lipitor Review and Lipitor Label ), BONIVA (IBANDRONATE SODIUM) (View Boniva (ibandronate Sodium) Review and Boniva (ibandronate Sodium) Label ), MIRALAX (View Miralax Review and Miralax Label ). Patient was hospitalized.

5366191-3 | Menopausal Symptoms, Upper Respiratory Tract Infection
Patient was taking Femring (View Usage). Patient experienced the following unwanted or unexpected effects: menopausal symptoms, upper respiratory tract infection on Jun 05, 2007 from UNITED STATES Additional patient health information: Female patient , 49 years of age, weighting 175.0 lb, was diagnosed with menopausal symptoms and. Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with CYMBALTA (View Cymbalta Review and Cymbalta Label ), PREVACID (View Prevacid Review and Prevacid Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), ALPRAZOLAM (View Alprazolam Review and Alprazolam Label ), HYDROCODONE (HYDROCODONE) (View Hydrocodone (hydrocodone) Review and Hydrocodone (hydrocodone) Label ), PERCOCET (View Percocet Review and Percocet Label ). Patient was hospitalized.

5348678-2 | Disease Recurrence, Hysterectomy, Menopausal Symptoms, Upper Respiratory Tract Infection
Adverse event was reported on May 24, 2007 by a Female patient taking Femring (View Usage) (Dosage: 0.05 Mg, Qd, Vaginal Ring) was diagnosed with menopausal symptoms and. Location: UNITED STATES , 49 years of age, weighting 175.0 lb, Patient had the following side effects: disease recurrence, hysterectomy (What is hysterectomy?), menopausal symptoms, upper respiratory tract infection. During the same period patient was treated with CYMBALTA (View Cymbalta Review and Cymbalta Label ), PREVACID (View Prevacid Review and Prevacid Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), ALPRAZOLAM (View Alprazolam Review and Alprazolam Label ), HYDROCODONE (HYDROCODONE) (View Hydrocodone (hydrocodone) Review and Hydrocodone (hydrocodone) Label ), PERCOCET (View Percocet Review and Percocet Label ). Patient was hospitalized.

5347896-7 | Amenorrhoea, Headache, Panic Attack, Sleep Disorder, Vaginal Haemorrhage
on Dec 19, 2006 Female patient from UNITED STATES , 43 years of age, weighting 136.9 lb, was diagnosed with urinary tract infection (What is urinary tract infection?) and was treated with Femring (View Usage). After Femring was administered, patient had the following side effects: amenorrhoea, headache (What is headache?), panic attack, sleep disorder (What is sleep disorder?), vaginal haemorrhage. Femring dosage: See Image.

5347894-3 | Breast Cancer
on Aug 03, 2006 Female patient from UNITED STATES , 61 years of age, was diagnosed with menopausal symptoms and was treated with Femring (View Usage). Patient experienced the following unwanted or unexpected effects: breast cancer (What is breast cancer?). Femring dosage: Vaginal. During the same period patient was treated with PREMARIN (Oral) (View Premarin Review and Premarin Label ).

5347891-8 | Uterine Cancer, Uterine Haemorrhage, Uterine Leiomyoma, Vaginal Haemorrhage
Patient was taking Femring (View Usage). Patient had the following side effects: uterine cancer (What is uterine cancer?), uterine haemorrhage, uterine leiomyoma, vaginal haemorrhage on Apr 24, 2006 from UNITED STATES Additional patient health information: Female patient , 54 years of age, weighting 130.1 lb, was diagnosed with hot flush, night sweats, vulvovaginal dryness and. Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with WELLBUTRIN SR (View Wellbutrin Sr Review and Wellbutrin Sr Label ).

5341169-4 | Angioedema, Chest Pain, Tachycardia
Adverse event was reported on May 17, 2007 by a Female patient taking Femring (View Usage) (Dosage: Qd, Vaginal) was diagnosed with hot flush and. Location: UNITED STATES , 38 years of age, weighting 127.0 lb, After Femring was administered, patient had the following side effects: angioedema, chest pain (What is chest pain?), tachycardia. During the same period patient was treated with EFFEXOR /01233801/(VENLAFAXINE0 (View Effexor /01233801/(venlafaxine0 Review and Effexor /01233801/(venlafaxine0 Label ), NEXIUM /01479302/ (ESOMEPRAZOLE MAGNESIUM) (View Nexium /01479302/ (esomeprazole Magnesium) Review and Nexium /01479302/ (esomeprazole Magnesium) Label ), ZYRTEC (View Zyrtec Review and Zyrtec Label ). Patient was hospitalized.

5330199-4 | Breast Swelling, Breast Tenderness, Glaucoma
on May 02, 2007 Female patient from UNITED STATES , 61 years of age, weighting 138.0 lb, was diagnosed with menopause (What is menopause?) and was treated with Femring (View Usage). Patient experienced the following unwanted or unexpected effects: breast swelling, breast tenderness, glaucoma (What is glaucoma?). Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with CABERGOLINE (View Cabergoline Review and Cabergoline Label ).

5303017-8 | Abdominal Pain, Dyspnoea, Hiatus Hernia, Medical Device Complication, Ovarian Cyst, Procedural Pain, Thyroid Disorder
on Mar 29, 2007 Female patient from UNITED STATES , 56 years of age, weighting 158.1 lb, was diagnosed with vulvovaginal dryness and was treated with Femring (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), dyspnoea, hiatus hernia, medical device complication, ovarian cyst (What is ovarian cyst?), procedural pain, thyroid disorder. Femring dosage: 0.05 Mg, Qd; Vaginal. During the same period patient was treated with SYNTHROID (View Synthroid Review and Synthroid Label ), DIOVAN HCT (View Diovan Hct Review and Diovan Hct Label ), PREVACID (View Prevacid Review and Prevacid Label ), NEXIUM (View Nexium Review and Nexium Label ), MULTIVITAMIN (View Multivitamin Review and Multivitamin Label ), FISH OIL (FISH OIL) (View Fish Oil (fish Oil) Review and Fish Oil (fish Oil) Label ), POTASSIUM (POTASSIUM) (View Potassium (potassium) Review and Potassium (potassium) Label ), CALCIUM (CALCIUM) (View Calcium (calcium) Review and Calcium (calcium) Label ). Patient was hospitalized.

5291499-X | Breast Tenderness, Hydrometra, Metrorrhagia, Ovarian Cyst, Therapeutic Response Unexpected
Patient was taking Femring (View Usage). After Femring was administered, patient had the following side effects: breast tenderness, hydrometra, metrorrhagia, ovarian cyst (What is ovarian cyst?), therapeutic response unexpected on Mar 22, 2007 from UNITED STATES Additional patient health information: Female patient , 57 years of age, weighting 130.1 lb, was diagnosed with menopause (What is menopause?) and. Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with WELLBUTRIN (View Wellbutrin Review and Wellbutrin Label ).

5291472-1 | Cystitis Interstitial, Pruritus Genital, Vulvovaginal Dryness, Weight Decreased
Adverse event was reported on Mar 21, 2007 by a Female patient taking Femring (View Usage) (Dosage: 0.05 Mg, Qd, Vaginal) was diagnosed with pruritus genital, vulvovaginal dryness and. Location: UNITED STATES , 58 years of age, weighting 115.1 lb, Patient experienced the following unwanted or unexpected effects: cystitis interstitial, pruritus genital, vulvovaginal dryness, weight decreased. During the same period patient was treated with SYNTHROID (View Synthroid Review and Synthroid Label ), ESTRADIOL (View Estradiol Review and Estradiol Label ), PROMETRIUM (View Prometrium Review and Prometrium Label ), PROTONIX /01263201/ (PANTOPRAZOLE) (View Protonix /01263201/ (pantoprazole) Review and Protonix /01263201/ (pantoprazole) Label ), PREMARIN /00073001/ (ESTROGENS CONJUGATED) (View Premarin /00073001/ (estrogens Conjugated) Review and Premarin /00073001/ (estrogens Conjugated) Label ).

5249126-3 | Abdominal Distension, Alopecia, Amnesia, Basal Cell Carcinoma, Breast Tenderness, Cardiac Pacemaker Insertion, Crying, Dermal Cyst, Disturbance In Attention
on Feb 08, 2007 Female patient from UNITED STATES , weighting 119.9 lb, was treated with Femring (View Usage). Patient had the following side effects: abdominal distension, alopecia, amnesia, basal cell carcinoma, breast tenderness, cardiac pacemaker insertion, crying, dermal cyst, disturbance in attention. Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with COUMADIN (View Coumadin Review and Coumadin Label ), LANOXIN (View Lanoxin Review and Lanoxin Label ), DILTIAZEM (View Diltiazem Review and Diltiazem Label ), PROMETRIUM (View Prometrium Review and Prometrium Label ), OXYTROL (OXYBUTYNIN) PATCH (View Oxytrol (oxybutynin) Patch Review and Oxytrol (oxybutynin) Patch Label ), POTASSIUM ACETATE (View Potassium Acetate Review and Potassium Acetate Label ), DIURETICS (View Diuretics Review and Diuretics Label ).

5199913-5 | Abdominal Distension, Alopecia, Amnesia, Breast Tenderness, Cardiac Pacemaker Insertion, Crying, Disturbance In Attention, Dysmenorrhoea
on Dec 21, 2006 Female patient from UNITED STATES , weighting 119.9 lb, was treated with Femring (View Usage). After Femring was administered, patient had the following side effects: abdominal distension, alopecia, amnesia, breast tenderness, cardiac pacemaker insertion, crying, disturbance in attention, dysmenorrhoea. Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with COUMADIN (View Coumadin Review and Coumadin Label ), LANOXIN (View Lanoxin Review and Lanoxin Label ), DILTIAZEM (View Diltiazem Review and Diltiazem Label ), PROMETRIUM (View Prometrium Review and Prometrium Label ), OXYTROL /00538901/ (OXYBUTYNIN) PATCH (View Oxytrol /00538901/ (oxybutynin) Patch Review and Oxytrol /00538901/ (oxybutynin) Patch Label ), POTASSIUM (POTASSIUM) (View Potassium (potassium) Review and Potassium (potassium) Label ), DIURETICS (View Diuretics Review and Diuretics Label ).

5199484-3 | Uterine Polyp, Vaginal Haemorrhage, Vulvovaginal Mycotic Infection
Patient was taking Femring (View Usage). Patient experienced the following unwanted or unexpected effects: uterine polyp, vaginal haemorrhage, vulvovaginal mycotic infection on Dec 18, 2006 from UNITED STATES Additional patient health information: Female patient , 56 years of age, weighting 145.1 lb, was diagnosed with vulvovaginal dryness and. Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with PREMPRO (View Prempro Review and Prempro Label ), VITAMINS (View Vitamins Review and Vitamins Label ), FOSAMAX (View Fosamax Review and Fosamax Label ).

5130176-2 | Breast Tenderness, Hydrometra, Metrorrhagia, Ovarian Cyst
Adverse event was reported on Sep 29, 2006 by a Female patient taking Femring (View Usage) (Dosage: 0.05 Mg, Qd, Vaginal) was diagnosed with menopausal symptoms and. Location: UNITED STATES , 57 years of age, weighting 130.1 lb, Patient had the following side effects: breast tenderness, hydrometra, metrorrhagia, ovarian cyst (What is ovarian cyst?). During the same period patient was treated with WELLBUTRIN (View Wellbutrin Review and Wellbutrin Label ).

5101961-8 | Breast Tenderness, Hydrometra, Metrorrhagia, Ovarian Cyst
on Aug 23, 2006 Female patient from UNITED STATES , 57 years of age, weighting 130.1 lb, was diagnosed with menopausal symptoms and was treated with Femring (View Usage). After Femring was administered, patient had the following side effects: breast tenderness, hydrometra, metrorrhagia, ovarian cyst (What is ovarian cyst?). Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with WELLBUTRIN (View Wellbutrin Review and Wellbutrin Label ).

4951466-X | Acne, Demyelination, Headache, Hot Flush, Hypoaesthesia, Neurological Symptom, Unevaluable Event
on Mar 07, 2006 Female patient from UNITED STATES , 32 years of age, weighting 220.0 lb, was treated with Femring (View Usage). Patient experienced the following unwanted or unexpected effects: acne (What is acne?), demyelination, headache (What is headache?), hot flush, hypoaesthesia, neurological symptom, unevaluable event. Femring dosage: 0.1 Mg, Qd, Vaginal. During the same period patient was treated with ZYRTEC (View Zyrtec Review and Zyrtec Label ), INDERAL (View Inderal Review and Inderal Label ). Patient was hospitalized.

4920806-X | Dyspareunia, Hyperkeratosis, Medical Device Complication, Post Procedural Complication, Rectocele, Vaginal Disorder, Vaginal Infection
Patient was taking Femring (View Usage). Patient had the following side effects: dyspareunia, hyperkeratosis, medical device complication, post procedural complication, rectocele, vaginal disorder, vaginal infection on May 13, 2004 from UNITED STATES Additional patient health information: Female patient , 61 years of age, weighting 155.9 lb, was diagnosed with menopausal symptoms and. Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with LIPITOR (View Lipitor Review and Lipitor Label ), PREMARIN (View Premarin Review and Premarin Label ), CALCIUM (CALCIUM) (View Calcium (calcium) Review and Calcium (calcium) Label ), ACTONEL (View Actonel Review and Actonel Label ).

4904812-7 | Hot Flush, Mood Swings, Night Sweats
Adverse event was reported on Feb 07, 2006 by a Female patient taking Femring (View Usage) (Dosage: 1 Ring Intravaginally Q 90 Days) was diagnosed with menopause (What is menopause?) and. Location: UNITED STATES , 41 years of age, weighting 180.0 lb, After Femring was administered, patient had the following side effects: hot flush, mood swings, night sweats.

4840389-2 | Vaginal Haemorrhage
on Aug 24, 2005 Female patient from UNITED STATES , 43 years of age, weighting 200.0 lb, was diagnosed with menopausal symptoms and was treated with Femring (View Usage). Patient experienced the following unwanted or unexpected effects: vaginal haemorrhage. Femring dosage: 0.1 Mg, Qd, Vaginal. During the same period patient was treated with TARKA (View Tarka Review and Tarka Label ), CLONIDINE (View Clonidine Review and Clonidine Label ), METHADONE HCL (View Methadone Hcl Review and Methadone Hcl Label ), PERCOCET (View Percocet Review and Percocet Label ), XANAX (View Xanax Review and Xanax Label ).

4806877-X | Mood Altered
on Oct 20, 2005 Female patient from UNITED STATES , 48 years of age, weighting 120.0 lb, was treated with Femring (View Usage). Patient had the following side effects: mood altered. Femring dosage: One Patch Applied Every 3 Months Transdermal. During the same period patient was treated with PROMETRIUM (View Prometrium Review and Prometrium Label ).

4803295-5 | Escherichia Vaginitis, Menstruation Irregular, Ovarian Cyst, Pelvic Infection, Vaginitis Bacterial, Vulvovaginal Mycotic Infection
Patient was taking Femring (View Usage). After Femring was administered, patient had the following side effects: escherichia vaginitis, menstruation irregular, ovarian cyst (What is ovarian cyst?), pelvic infection, vaginitis bacterial, vulvovaginal mycotic infection on Sep 29, 2005 from UNITED STATES Additional patient health information: Female patient , 41 years of age, weighting 130.1 lb, was diagnosed with menopausal symptoms and. Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with PROZAC (View Prozac Review and Prozac Label ).

4790441-5 | Ileal Perforation, Intestinal Obstruction, Post Procedural Complication, Sepsis, White Blood Cell Count Increased
Adverse event was reported on Sep 21, 2005 by a Female patient taking Femring (View Usage) (Dosage: 0.1 Mg, Qd, Vaginal) was diagnosed with menopausal symptoms and. Location: UNITED STATES , 63 years of age, weighting 149.9 lb, Patient experienced the following unwanted or unexpected effects: ileal perforation, intestinal obstruction, post procedural complication, sepsis (What is sepsis?), white blood cell count increased. During the same period patient was treated with ACETYLSALICYLIC ACID SRT (View Acetylsalicylic Acid Srt Review and Acetylsalicylic Acid Srt Label ), ALTACE (View Altace Review and Altace Label ). Patient was hospitalized.

4779567-X | Diarrhoea, Fall, Foot Fracture, Hot Flush, Medical Device Complication, Migraine, Motion Sickness, Nausea, Pulmonary Embolism
on Dec 04, 2004 Female patient from UNITED STATES , 52 years of age, weighting 173.1 lb, was diagnosed with menopausal symptoms and was treated with Femring (View Usage). Patient had the following side effects: diarrhoea, fall (What is fall?), foot fracture, hot flush, medical device complication, migraine (What is migraine?), motion sickness (What is motion sickness?), nausea (What is nausea?), pulmonary embolism (What is pulmonary embolism?). Femring dosage: See Image. During the same period patient was treated with VIOXX (View Vioxx Review and Vioxx Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), REMICADE (View Remicade Review and Remicade Label ), PREVACID (View Prevacid Review and Prevacid Label ), ZANTAC (View Zantac Review and Zantac Label ), IMITREX (View Imitrex Review and Imitrex Label ), BEXTRA (View Bextra Review and Bextra Label ). Patient was hospitalized.

4779406-7 | Back Pain, Bladder Disorder, Bladder Prolapse, Device Migration, Implant Expulsion, Pain In Extremity, Urinary Incontinence, Uterine Prolapse
on Dec 04, 2004 Female patient from UNITED STATES , 60 years of age, was diagnosed with vulvovaginal dryness and was treated with Femring (View Usage). After Femring was administered, patient had the following side effects: back pain (What is back pain?), bladder disorder, bladder prolapse, device migration, implant expulsion, pain in extremity, urinary incontinence (What is urinary incontinence?), uterine prolapse. Femring dosage: Qd, Vaginal.

4778111-0 | Intestinal Obstruction, Intestinal Perforation
Patient was taking Femring (View Usage). Patient experienced the following unwanted or unexpected effects: intestinal obstruction, intestinal perforation on Sep 07, 2005 from UNITED STATES Additional patient health information: Female patient , 63 years of age, weighting 149.9 lb, was diagnosed with menopausal symptoms and. Femring dosage: 0.1 Mg, Qd, Vaginal. During the same period patient was treated with ACETYLSALICYLIC ACID SRT (View Acetylsalicylic Acid Srt Review and Acetylsalicylic Acid Srt Label ), ALTACE (View Altace Review and Altace Label ), FEMRING (ESTRADIOL ACETATE) VAGINAL (View Femring (estradiol Acetate) Vaginal Review and Femring (estradiol Acetate) Vaginal Label ). Patient was hospitalized.

4763405-5 | Oral Mucosal Discolouration, Swollen Tongue, Tongue Disorder, Tongue Neoplasm
Adverse event was reported on Aug 19, 2005 by a Female patient taking Femring (View Usage) (Dosage: 0.05 Mg, Qd, Vaginal) . Location: UNITED STATES , 58 years of age, weighting 134.9 lb, Patient had the following side effects: oral mucosal discolouration, swollen tongue, tongue disorder, tongue neoplasm. During the same period patient was treated with MULTIVITAMINS (PANTHENOL, ASCORBIC ACID, ERGOCALCIFEROL, FOLIC ACID, N (View Multivitamins (panthenol, Ascorbic Acid, Ergocalciferol, Folic Acid, N Review and Multivitamins (panthenol, Ascorbic Acid, Ergocalciferol, Folic Acid, N Label ).

4717937-6 | Breast Disorder Female, Fibrocystic Breast Disease
on May 18, 2005 Female patient from UNITED STATES , 56 years of age, weighting 149.9 lb, was diagnosed with hot flush and was treated with Femring (View Usage). After Femring was administered, patient had the following side effects: breast disorder female, fibrocystic breast disease. Femring dosage: 0.05 Mg, Qd, Vaginal. During the same period patient was treated with FOSAMAX (View Fosamax Review and Fosamax Label ), CALCIUM (CALCIUM) (View Calcium (calcium) Review and Calcium (calcium) Label ), MULTIVITAMINS (ASCORBIC ACID, ERGOCALCIFEROL, FOLIC ACID, NICOTINAMIDE (View Multivitamins (ascorbic Acid, Ergocalciferol, Folic Acid, Nicotinamide Review and Multivitamins (ascorbic Acid, Ergocalciferol, Folic Acid, Nicotinamide Label ), ASPIRIN (View Aspirin Review and Aspirin Label ).

4696559-X | Blood Pressure Increased, Chest Pain, Fungal Infection, Migraine, Muscle Spasms, Vision Blurred
on Jun 10, 2005 Female patient from , 49 years of age, weighting 134.9 lb, was treated with Femring (View Usage). Patient experienced the following unwanted or unexpected effects: blood pressure increased, chest pain (What is chest pain?), fungal infection (What is fungal infection?), migraine (What is migraine?), muscle spasms, vision blurred. Femring dosage: 0.05 Mg, Qd, Vaginal.

4691423-4 | Breast Mass, Dyspareunia, Vulvovaginal Discomfort
Patient was taking Femring (View Usage). Patient had the following side effects: breast mass, dyspareunia, vulvovaginal discomfort on May 27, 2005 from Additional patient health information: Female patient , 53 years of age, weighting 173.1 lb, . Femring dosage: 0.05 Mg, Qd, Vaginal.